Understanding the Benefits of Cannabidiol in Children with Autism Spectrum Disorder

Brief description of study

There is currently no pharmacological treatment for autism spectrum disorder (ASD), but research has shown that cannabidiol (CBD) might be helpful for improving social and communication difficulties, as well as common symptoms like anxiety, irritability, and sleep problems. Our researchers in child psychiatry and epilepsy at NYU Langone are studying the potential therapeutic benefits of CBD in children and teens with ASD. CBD is a compound of the cannabis plant that does not produce intoxicating effects and has been well tolerated by children and adolescents with relatively low side effects. In this study, participants will be given CBD at one of three doses for 6 weeks to examine the benefits and side effects that may be associated. The purpose of this study is to see if CBD may help improve core symptoms of ASD and/or symptoms associated with ASD in children and adolescents. CBD is considered experimental, as the United States Food and Drug Administration (FDA) has not approved it to treat ASD.


Clinical Study Identifier: s18-00250
ClinicalTrials.gov Identifier: NCT03900923
Principal Investigator: Francisco X Castellanos
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.